Adage Capital Partners Gp, L.L.C. Caribou Biosciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.82 - $8.26 $241,000 - $413,000	-50,000 Reduced 24.52%	153,933 $791,000
Q4 2023 Feb 14, 2024	SELL	$3.58 - $6.25 $179,000 - $312,500	-50,000 Reduced 19.69%	203,933 $1.17 Million
Q2 2023 Aug 14, 2023	SELL	$4.04 - $5.47 $133,724 - $181,057	-33,100 Reduced 11.53%	253,933 $1.08 Million
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $334,200 - $660,600	-60,000 Reduced 17.29%	287,033 $1.8 Million
Q3 2022 Nov 14, 2022	SELL	$5.34 - $12.79 $133,500 - $319,750	-25,000 Reduced 6.72%	347,033 $3.66 Million
Q2 2022 Aug 15, 2022	SELL	$5.1 - $9.74 $1.21 Million - $2.31 Million	-237,034 Reduced 38.92%	372,033 $2.02 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $9.59 Million - $18.4 Million	609,067 New	609,067 $14.5 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $123M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.